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Abstract
Background: Community-acquired pneumonia (CAP) is a major global disease. Parapneumonic effusions often complicate CAP
and range from uninfected (simple) to infected (complicated) parapneumonic effusions and empyema (pus). CAP patients who have a
pleural effusion at presentation are more likely to require hospitalization, have a longer length of stay and higher mortality than those
without an effusion. Conventional management of pleural infection, with antibiotics and chest tube drainage, fails in about 30% of
cases. Several randomized controlled trials (RCT) have evaluated the use of corticosteroids in CAP and demonstrated some potential
benefits. Importantly, steroid use in pneumonia has an acceptable safety profile with no adverse impact on mortality. A RCT focused
on pediatric patients with pneumonia and a parapneumonic effusion demonstrated shorter time to recovery. The effects of
corticosteroid use on clinical outcomes in adults with parapneumonic effusions have not been tested. We hypothesize that
parapneumonic effusions develop from an exaggerated pleural inflammatory response. Treatment with systemic steroids may
dampen the inflammation and lead to improved clinical outcomes. The steroid therapy and outcome of parapneumonic pleural
effusions (STOPPE) trial will assess the efficacy and safety of systemic corticosteroid as an adjunct therapy in adult patients with CAP
and pleural effusions.
Methods: STOPPE is a pilot multicenter, double-blinded, placebo-controlled RCT that will randomize 80 patients with
parapneumonic effusions (2:1) to intravenous dexamethasone or placebo, administered twice daily for 48hours. This exploratory
study will capture a wide range of clinically relevant endpoints which have been used in clinical trials of pneumonia and/or pleural
infection; including, but not limited to: time to clinical stability, inflammatorymarkers, quality of life, length of hospital stay, proportion of
patients requiring escalation of care (thoracostomy or thoracoscopy), and mortality. Safety will be assessed by monitoring for the
incidence of adverse events during the study.
Discussion: STOPPE is the first trial to assess the efficacy and safety profile of systemic corticosteroids in adults with CAP and
pleural effusions. This will inform future studies on feasibility and appropriate trial endpoints.
Trial registration: ACTRN12618000947202
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1. Introduction
Community-acquired pneumonia (CAP) is a major global
disease.[1] Pneumonia (including influenza) is currently the 8th
leading cause of death in the United States[2] and lower
respiratory tract infections were the 3rd leading cause of death
worldwide in 2015.[3] CAP incurs significant, immediate,
healthcare costs as well as economic costs of time lost from
work/school and adverse long-term health problems in survi-
vors.[4,5]
Parapneumonic effusions complicate 18% to 57% of cases of
pneumonia.[6–8] CAP with an effusion is associated with worse
outcomes. In one large study of 4700 patients with CAP, those
with an effusion at the time of presentation to the emergency
department were more likely to require hospitalization and had a
length of stay twice that of those without an effusion.[9]
Parapneumonic effusions, inadequately treated, may progress
to complicated parapneumonic effusions or empyema, both of
which have risen in incidence in recent years.[10,11] Conventional
management of pleural infection, with antibiotics and chest tube
drainage, fails in about 30% of cases. Many of these patients are
frail and unsuitable for surgical management and mortality
remains high at 8% in hospital and 20% at 3 months.[11] This
mortality rate has increased over the past 2 decades, despite
advances in antimicrobial therapy.[12]
The pathobiology of pleural effusion formation secondary to
pneumonia is not fully understood. One hypothesis is that an
over-exaggerated inflammatory response triggered by the infec-
tion plays a critical role and may be a target for treatment.
Steroids have been shown to be successful adjunct therapies in
pneumococcal meningitis and Pneumocystis jirovecii pneumonia,
likely due to the significant inflammatory component of these
conditions.[13,14] The role of systemic corticosteroids as adjunct
treatment in pneumonia is a controversial topic with inconsistent
results on mortality from large randomized contolled trials
(RCTs).[15] The majority of studies have, however, demonstrated
benefits of steroids in shortening time to resolution of fever and
clinical stability.[16–22] Importantly, all the studies have demon-
strated that use of steroids, even in severe pneumonia, was safe
with no adverse impact on mortality.[23,24]
The effects of corticosteroid use on clinical outcomes in adults
with parapneumonic effusions have not been tested, however,
evidence exists in support of the hypothesis that parapneumonic
effusions develop from an exaggerated immune response.
Patients on long-term inhaled corticosteroids were much less
likely to develop a parapneumonic effusion compared with those
who were not, and in those who developed a parapneumonic
effusion, it was significantly smaller in volume with lower
inflammatory indices.[25] Similarly, addition of prednisolone
offered faster symptomatic improvement over placebo without
major side effects in tuberculosis pleural effusions.[26] Only one
study has directly assessed the impact of steroids in para-
pneumonic effusion. This RCT of pediatric patients found that
children treated with dexamethasone infusion had a shorter time
to recovery without detrimental impact, except for transient
hyperglycemia.[27] These findings strongly support evaluation of
the role of adjunct corticosteroid therapy in adults with
pneumonia and associated pleural effusions.
The steroid therapy and outcome of parapneumonic pleural
effusions (STOPPE) trial is a pilot multicenter, double-blinded,
placebo-controlled RCT designed to assess the efficacy and safety
of systemic corticosteroid as an adjunct therapy in patients with
parapneumonic pleural effusions. The primary hypothesis is that
systemic corticosteroids will improve clinical outcome (by
reducing pleural and systemic inflammation) in patients with
pneumonia-related pleural effusions, and have an acceptable
safety profile.
2. Methods
2.1. Study design and participants
STOPPE is a multicenter, double-blinded, placebo-controlled
RCT which will recruit participants with parapneumonic
effusion. Participants will be randomized 2:1 to receive
intravenous dexamethasone (4mg twice daily for 48hours) or
placebo. This study will follow participants through their
hospital admission and at outpatient visits after 14 days, 30
days, 6 months, and 12 months (Table 1).
Patients with community-acquired pneumonia will be identi-
fied on hospital admission to the General Medicine and
Respiratory teams. Those who have a pleural effusion either
on admission or develop one within the following 72hours will
be identified. Any patient that meets the inclusion criteria, and
none of the exclusion criteria, will be approached by a member of
the research team and offered inclusion in the trial. Informed
consent will be obtained prior to enrolment. Screening logs will
be kept.
Inclusion criteria: New pleural effusion on chest radiography
(with bedside ultrasound confirmation) with clinical evidence of a
community-acquired pneumonia as per clinician assessment and
no alternative causes identified.
Exclusion criteria (similar to those used in recent large
multicenter trials of corticosteroid use in pneumonia):
1. Age <18 years;
2. Hemodynamic/respiratory instability requiring intensive
care;
3. Acute burn injury;
4. Gastrointestinal bleeding in the last 3 months;
5. Known adrenal insufficiency;
6. Other indication for steroids (e.g., asthma/COPD exacerba-
tion);
7. Long-term steroid use (≥10mg/d prednisolone equivalent);
8. Acute delirium;
9. Previous steroid-induced psychosis;
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10. Severe immunodeficiency (e.g., HIV infection and CD4 count
<350cells/mL), immunosuppressive therapy after organ
transplant, leukocytopenia (<1109/L);
11. Cystic fibrosis;
12. Active tuberculosis;
13. Pregnancy/lactation;
14. Un-correctable bleeding diathesis;
15. Poorly-controlled diabetes mellitus (DM);
16. Blood glucose level over 20mmol/L at the time of screening;
and
17. Inability to consent.
2.2. Interventions
This trial will randomize participants to receive either dexametha-
sone4mgorplaceboadministeredas an intravenous infusion every
12hours for 48hours, that is, to a total of 4 doses. Dexamethasone
will be diluted in 100mL of normal saline and administered via a
standard intravenous administration line as a 15-minute infusion.
The placebo arm will receive 100mL of normal saline similarly
administered via standard intravenous administration line. Once
randomized, the hospital pharmacy will prepare the assigned drug
(or placebo). Participants, clinicians, nursing staff, and the research
team will be blinded to the treatment arm.
Participants may be withdrawn from the trial if they develop a
severe adverse event (SAE). After the identification of a SAE
during administration of study drug, dexamethasone/placebo
administration may be interrupted for up to 24hours at the
discretion of the local principal investigator and restarted if
clinically appropriate to complete the delayed trial treatment
course. Participants may also withdraw from the trial at any time
if they so wish.
Participants will be able to take their usual medications during
the study. Any changes required will be discussed with the
participant prior to recruitment. A note of all medications will be
taken before the start of the study and will be entered on to the
participant’s medication log.
2.3. Outcomes
As a pilot and first study of corticosteroid in adults with
pneumonia-related pleural effusions, we aim to capture a wide
range of clinically relevant endpoints which have been used in
clinical trials of pneumonia and/or pleural infection, and are
considered by clinicians as important. These include:
1. The time to clinical stability defined as the time in hours for
all of the following parameters to have beenmaintained for at
least 12hours: temperature 37.4°, heart rate 100bpm,
respiratory rate 20/min, oxygen saturations ≥95% on
room air (unless on home oxygen), systolic blood pressure
≥90mmHg and tolerating oral intake or discharge home
(determined by the treating physician)[28];
2. The time in hours for each of the above parameters to have
been maintained for least 12hours;
3. Change in leukocyte count andC-reactive protein (CRP) over
time (Day 0, 1, 3, 14±2 days, 30±2 days);
4. Proportion of participants with a normal leukocyte count
and CRP at Day 14±2 and Day 30±2;
5. Improvement in pleural effusion including size of pleural
opacity as percentage of hemithorax (as used in our prior
studies)[29] over the first 14±2 days and at Day 30±2
comparedwith baseline; andproportion of participantswhose
effusion has resolved at day 14±2 days and day 30±2;
6. Proportion of participants requiring an invasive pleural
procedure including therapeutic aspirate (volume >200mL)
or chest drain insertion at <48hours and >48hours post-
commencement of treatment. If intercostal catheter is
inserted, the following will be recorded:
Table 1
Schedule of enrolment, intervention, data collection, and assessment.
Index Post randomization Discharge post t0 Months (safety review)
Days Days Months
Procedures T0 1 2 3 ±5 Discharge 14 (±2 days) 30 (±2 days) 6 (±7 days) 12 (±7 days)
Clinical assessment x x x x x x x x x x
Bedside ultrasound x x x
Informed consent x
Concomitant medications x x x x x x x x
Randomization (IVRS) x
Baseline data CRF completion x
Questionnaire: SF-36 QOL x x x
Observations (every 4hours: temperature,
pulse, bp, respiratory rate, O2 saturations)
x x x x x
Dexamethasone or placebo infusion†
(start within 24hours of enrolment.)
x x
CXR x x x x x x x
Bloods
∗
x x x x x x x
Capillary blood glucose test (every 6hours) x x x
Adverse event review x x x x x x x x
Actigraph to participant—lead site only
(start at discharge)
x x
Hospital admission review x x x x
Spirometry x x
∗
Mandatory blood tests=WCC and CRP.
† Dexamethasone/placebo every 12hours for 48hours—in 100mLs N/Saline over 15mins= total of 4 doses.
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a. Duration of chest tube drainage;
b. Volume of fluid drained daily;
c. Proportion treated with intrapleural fibrinolytic therapy;
and
d. Proportion requiring additional drainage procedures
including additional chest drain insertion and therapeutic
thoracentesis.
7. Proportion of patients referred for thoracic surgery;
8. Duration of antibiotic therapy (intravenous and oral);
9. Length of hospital stay from commencement of treatment to
discharge or death;
10. Quality of life measurements including Short form-36 (SF-
36) questionnaire[30] and actigraphy (see Section 2.7 for
details);
11. Adverse events including but not limited to hyperglycemia,
insulin use, need for intensive care, nosocomial infection,
gastrointestinal bleeding and re-admission to hospital of any
cause; and
12. Overall survival.
2.4. Sample size
In the absence of existing data, this pilot study aims to recruit 80
participants over 18 months. This will allow inclusion of the full
range of parapneumonic effusions at various stages from simple
parapneumonic stage (most common) to empyema (about 5–
10% of all cases). The 2:1 randomization strategy will include
50+ participants into the dexamethasone arm to increase the
power of detecting treatment related adverse events. The results
of this pilot study will inform the power calculation of future
studies and determine the most appropriate endpoints of future
trials. Past evidence and data suggest that we will be able to
estimate a range of outcome parameters with a high enough
degree of accuracy with a sample size of 80 and allow some initial
comparisons between treatment and placebo. The number of
patients included over this timeframe will inform the feasibility
and design of further studies.
2.5. Randomization and blinding
Participants will be randomly assigned (2:1) to receive intrave-
nous dexamethasone or placebo. The National Health and
Medical Research Council Clinical Trials Centre, Sydney,
Australia provides the randomization setup via their automated
telephone-based interactive voice response services. Randomiza-
tion is minimized for:
(i) A score of <2 versus ≥2 using the predictive score of
Chalmers et al[6] for the development of complicated pleural
effusion/empyema secondary to pneumonia (one point each
for: serum albumin <30g/L, CRP >100mg/L, platelet count
>400109/L, serum sodium <130mmol/L, intravenous
drug use, and chronic alcohol excess. One point will be
deducted for the presence of COPD);
(ii) Known history of diabetes mellitus (vs not); and
(iii) Size of the effusion on chest radiograph (a grading of 2 vs
>2 and/or having an intercostal catheter in place).[31]
The research team, treating physician, nursing staff, and
participant will be blinded to the treatment arm. Only pharmacy
staff will receive unblinded randomization information in order
to prepare the study drug or placebo. In the event that unblinding
is required, a designated member of the lead research teamwill be
contacted and will follow the unblinding SOP.
2.6. Data collection
Recruited participants will have their baseline data collected
including chest radiograph appearances, blood tests (total
leukocyte count, CRP) and clinical observations, as shown in
Table 1. These parameters will be repeated through the
participant’s hospitalization and on discharge. Participants will
be monitored for adverse events and those requiring interven-
tional management will be noted. All participants will have a
capillary blood glucose test four times a day. Participants will be
asked to complete the SF-36 quality of life questionnaire at their
date of recruitment, at time of hospital discharge and at the Day
30 follow-up visit. Additional blood tests and imaging will be
performed at the discretion of the treating physicians. At the 6
and 12 months follow-up visits data on chest x-ray, spirometry,
and adverse events will be collected.
Physical activity patterns will be evaluated by a well-validated
triaxial accelerometer (ActiGraph GT3X+, Pensacola, FL). The
accelerometer will be worn for a 7-day period post-discharge and
also from day 30. Participants will fill an activity log while
wearing the accelerometer. This objective measurement of
physical function has been studied predominantly in people
with malignant disease and is expected to be a useful adjunct in
assessment of recovery from pneumonia in the future.[32]
Accelerometry will be performed on participants at the lead
site only.
Where participants do not attend planned study visits the
research staff will contact them at home to determine the reason
and book an additional visit if required. If the participant misses a
visit due to an admission to the site hospital, the visit will be
carried out in the hospital providing the participant is well
enough. Where this is not possible and the visit is missed, a File
Note will be created and kept in the participant’s study file.
Study visits are carried out according to the individual
participant’s visit schedule.
2.7. Data management
Data collected will be stored at site on password-protected
computers accessible only by the site research staff and will be
held in the department where the principal investigator (PI) is
based.
Data entered will be checked by a second staff to ensure
accuracy. All physical documentation will be stored in a secure
environment in line with the Australian Code for the Responsible
Conduct of Research for clinical trials and local policy guidelines
for research data archiving.
2.8. Statistical methods
Data will be analyzed on an intention-to-treat basis. Intergroup
comparison will be conducted using Student t test or Mann–
Whitney U rank sum test (for parametric and non-parametric
distributions, respectively). Changes in parameters before and
after treatment within the same subject will be analyzed using a
paired t test or Wilcoxon signed rank test. Correlations will be
analyzed using Pearson or Spearman tests. Multivariate analyses
may be performed if indicated. P< .05 will be considered
statistically significant in the data analyses.
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2.9. Data monitoring
The Trial Steering Committee will be responsible for the
supervision of the trial in all its aspects. It will be responsible
for ensuring the completion of the trial to clinical and ethical
standards. The Data Safety Monitoring Committee will ensure
the safety of study participants through study procedures,
reviewing adverse events and serious adverse events, and consider
new data (recently published studies) that may determine the
validity of study continuation. All deaths, anticipated or
unanticipated, will be discussed with the Data Safety Monitoring
Committee (DSMC). The committee determines whether signifi-
cant benefits or risks have been uncovered which may have an
impact on the feasibility and/or ethical conduct of the study. The
DSMC will also help to ensure the scientific integrity of the study
by reviewing the quality of the data it uses to make its decisions.
All serious and non-serious adverse events (AEs) relating to the
study will be fully documented on the appropriate case report
forms (CRFs). For each AE, the investigator will provide the onset
and end dates, intensity, treatment required, outcome, serious-
ness and action taken. AE logs will be followed up until
resolution. Where AEs are not resolved at study completion this
will be noted on the AE log.
2.10. Ethics and dissemination
The trial has been approved by the Sir Charles Gairdner and
Osborne Park Health Care Group Human Research Ethics
Committee. Recruitment centers include Sir Charles Gairdner,
Fiona Stanley, St John of God Midland, and Royal Perth
Hospitals in Western Australia and Northern Hospital in
Victoria—approved through the National Mutual Acceptance
scheme. Further sites are expected to join.
The investigators will receive approval from the ethics
committee for any amendment to the protocol and ensure it is
signed by any patient subsequently entering into the trial and
those currently in the study, if affected by the amendment.
Results of the clinical trial will be presented at scientific
meetings and published in medical journals when the trial is
completed.
3. Discussion
Parapneumonic effusion causes significant morbidity and
mortality worldwide and its incidence continues to rise despite
advances in anti-microbial therapy.[10,11] Conventional man-
agement with antibiotics and chest tube drainage fails in about
30% of cases. Many of these patients are frail and unsuitable
for surgical management and mortality remains high. This
highlights the need for further therapeutic options in the
treatment of parapneumonic effusions. Halting the progression/
development of parapneumonic effusions could represent a
novel approach.
Dexamethasone is a corticosteroid with predominantly anti-
inflammatory effects when compared with alternative corticoste-
roids. It has been used in the management of many inflammatory
conditions. Most of the side effects of dexamethasone are due to
long term use and have been well documented. Reassuringly the
recent RCTs using short term corticosteroid in CAP patients
found no increased incidence of superinfection or gastrointestinal
bleeding in the treatment arms. However, the efficacy and safety
profiles of dexamethasone in the treatment of parapneumonic
effusions in adults have not been studied.
Therefore, the STOPPE trial was designed as the first step
towards assessing the efficacy and safety of systemic corticoste-
roids as an adjunct therapy in adult patients with parapneumonic
pleural effusions. This clinical trial will capture a wide range of
clinically relevant endpoints on potential roles of corticosteroids
in patients with parapneumonic effusions. The results will inform
the design of future studies.
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